"You need to test this."
CEO James Brown, discussing the pending trial of DUR-928 in COVID-19 patients with severe liver and kidney damage in the May 11 conference call: "My sense is the trial will start soon rather than later. I can't give an exact date, but we are getting close... We're in good shape to be able to start the trial as quickly as possible...with 928, we have an opportunity to be able to approach the whole thing in a different way...from the very beginning of this--in early March, we've had a huge number of thought leaders, who have worked with us on 928...have come forward and said you need to test this. This needs to be tested in these patients."